CN106255688B - 吗啉-吡啶衍生物 - Google Patents

吗啉-吡啶衍生物 Download PDF

Info

Publication number
CN106255688B
CN106255688B CN201580022457.5A CN201580022457A CN106255688B CN 106255688 B CN106255688 B CN 106255688B CN 201580022457 A CN201580022457 A CN 201580022457A CN 106255688 B CN106255688 B CN 106255688B
Authority
CN
China
Prior art keywords
morpholin
pyridyl
pyrazole
carboxamide
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580022457.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106255688A (zh
Inventor
吉多·加利
菲利普·普夫利格
罗杰·诺克罗斯
朱塞佩·切切里
沈宏
胡逸民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN106255688A publication Critical patent/CN106255688A/zh
Application granted granted Critical
Publication of CN106255688B publication Critical patent/CN106255688B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201580022457.5A 2014-04-30 2015-04-27 吗啉-吡啶衍生物 Expired - Fee Related CN106255688B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/076623 2014-04-30
PCT/CN2014/076623 WO2015165085A1 (en) 2014-04-30 2014-04-30 Morpholin-pyridine derivatives
PCT/EP2015/059002 WO2015165835A1 (en) 2014-04-30 2015-04-27 Morpholin-pyridine derivatives

Publications (2)

Publication Number Publication Date
CN106255688A CN106255688A (zh) 2016-12-21
CN106255688B true CN106255688B (zh) 2019-11-08

Family

ID=53174989

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580022457.5A Expired - Fee Related CN106255688B (zh) 2014-04-30 2015-04-27 吗啉-吡啶衍生物

Country Status (12)

Country Link
US (1) US9840501B2 (enExample)
EP (1) EP3137459B1 (enExample)
JP (1) JP6255516B2 (enExample)
KR (1) KR101842382B1 (enExample)
CN (1) CN106255688B (enExample)
AR (1) AR100210A1 (enExample)
BR (1) BR112016022796B1 (enExample)
CA (1) CA2943575C (enExample)
MX (1) MX377195B (enExample)
RU (1) RU2690154C2 (enExample)
TW (1) TWI576345B (enExample)
WO (2) WO2015165085A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046008T2 (hu) 2014-07-17 2020-02-28 Sunshine Lake Pharma Co Ltd I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
CR20180443A (es) * 2016-03-17 2018-11-21 Hoffmann La Roche Derivado de morfolina
WO2017210616A1 (en) * 2016-06-02 2017-12-07 Purdue Pharma L.P. Trace amine associated receptor 1 agonists and partial agonists for pain treatment
CN113754580B (zh) * 2020-06-05 2023-04-25 上海中泽医药科技有限公司 一种吡啶吗啉类化合物、其制备方法及其应用
US20250051316A1 (en) 2021-11-04 2025-02-13 Shanghai Hansoh Biomedical Co., Ltd. 2-(aryl-2-yl) morpholine and deuterated derivative thereof, preparation method therefor and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101578271A (zh) * 2006-12-18 2009-11-11 弗·哈夫曼-拉罗切有限公司 作为taar的配体的4-咪唑啉化合物
CN102686563A (zh) * 2009-12-22 2012-09-19 霍夫曼-拉罗奇有限公司 取代的苯甲酰胺衍生物
CN103443074A (zh) * 2011-03-24 2013-12-11 霍夫曼-拉罗奇有限公司 杂环胺衍生物
CN103596567A (zh) * 2011-06-09 2014-02-19 霍夫曼-拉罗奇有限公司 吡唑衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
WO2013173506A2 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101578271A (zh) * 2006-12-18 2009-11-11 弗·哈夫曼-拉罗切有限公司 作为taar的配体的4-咪唑啉化合物
CN102686563A (zh) * 2009-12-22 2012-09-19 霍夫曼-拉罗奇有限公司 取代的苯甲酰胺衍生物
CN103443074A (zh) * 2011-03-24 2013-12-11 霍夫曼-拉罗奇有限公司 杂环胺衍生物
CN103596567A (zh) * 2011-06-09 2014-02-19 霍夫曼-拉罗奇有限公司 吡唑衍生物

Also Published As

Publication number Publication date
CA2943575A1 (en) 2015-11-05
JP6255516B2 (ja) 2017-12-27
WO2015165085A1 (en) 2015-11-05
CA2943575C (en) 2022-08-30
CN106255688A (zh) 2016-12-21
US9840501B2 (en) 2017-12-12
AR100210A1 (es) 2016-09-21
BR112016022796B1 (pt) 2023-03-07
BR112016022796A2 (enExample) 2017-08-15
RU2690154C2 (ru) 2019-05-31
TWI576345B (zh) 2017-04-01
MX377195B (es) 2025-03-07
US20170044145A1 (en) 2017-02-16
EP3137459B1 (en) 2018-05-23
MX2016013412A (es) 2017-01-18
RU2016146560A3 (enExample) 2018-11-26
RU2016146560A (ru) 2018-06-01
TW201546067A (zh) 2015-12-16
WO2015165835A1 (en) 2015-11-05
EP3137459A1 (en) 2017-03-08
KR101842382B1 (ko) 2018-03-26
JP2017513912A (ja) 2017-06-01
KR20160147033A (ko) 2016-12-21

Similar Documents

Publication Publication Date Title
CN103443074B (zh) 杂环胺衍生物
CN106661043B (zh) 2-氧杂-5-氮杂双环[2.2.1]庚-3-基衍生物
CN107001259B (zh) 作为taar配体的取代的氮杂环丁烷衍生物
CN106255688B (zh) 吗啉-吡啶衍生物
CN103596937A (zh) 取代的苯甲酰胺衍生物
CN104024250A (zh) 作为痕量胺相关受体(taar)的杂环衍生物
CN107903251A (zh) 作为用于治疗数种疾病如抑郁症、糖尿病和帕金森病的taar调节剂的吡唑甲酰胺衍生物
CN106459073B (zh) 作为taar1调节剂的5-氧杂-2-氮杂二环[2.2.2]辛-4-基和5-氧杂-2-氮杂二环[2.2.1]庚-4-基衍生物
HK1228379B (zh) 吗啉-吡啶衍生物
HK1228379A1 (en) Morpholin-pyridine derivatives
HK1235395B (zh) 作爲taar配体的取代的氮杂环丁烷衍生物
HK1230196B (zh) 作为taar1调节剂的5‑氧杂‑2‑氮杂二环[2．2．2]辛‑4‑基和5‑氧杂‑2‑氮杂二环[2．2．1]庚‑4‑基衍生物
HK1232869B (zh) 2-氧杂-5-氮杂双环[2．2．1]庚-3-基衍生物
HK1235395A1 (en) Substituted azetidine derivatives as taar ligands
HK1230196A1 (en) 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as taar1 modulators
HK1234389B (zh) 作为taar调节剂的6-氨基-5，6，7，8-四氢萘-2-基或3-氨基色满-7-基衍生物
HK1232869A1 (en) 2-oxa-5-azabicyclo [2.2.1] heptan-3-yl derivatives
CN106470994A (zh) 用于治疗cns疾病的取代的吡嗪并[2,1‑a]异喹啉衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1228379

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191108

CF01 Termination of patent right due to non-payment of annual fee